Appointment of Dr. Mauricio Futran (DIN: 11699767), as an Additional Director of the Company categorized as Non-Executive Non-Independent
NEULANDLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Neuland Laboratories Limited announced the appointment of Dr. Mauricio Futran (DIN: 11699767) as an Additional Director, categorized as Non-Executive Non-Independent, effective May 12, 2026. The appointment follows the recommendation of the Nomination and Remuneration Committee and is subject to shareholder approval at the ensuing 42nd Annual General Meeting scheduled for August 4, 2026. Alongside this, the company reported strong FY 2025-26 financial results with revenue from operations of Rs. 20,229.85 million (up 37% YoY), profit after tax of Rs. 3,639.98 million on consolidated basis, and EPS of Rs. 283.71. The Board also recommended a final dividend of Rs. 34 per equity share (340% on face value Rs. 10) with record date July 24, 2026. Additionally, the company approved capacity expansion of 120.5 KL at its Unit 1 in Telangana with an investment of Rs. 143.4 crores over 12-18 months to meet growing customer demand.
Positive signals for shareholders with strong financial performance, attractive dividend payout, and board strengthening through a new director appointment. The capacity expansion signals confidence in future demand growth.